A liquid biopsy assay for the noninvasive detection of lymph node metastases in T1 lung adenocarcinoma
Thoracic Cancer · 2024
DOI: 10.1111/1759-7714.15315 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2024. Verfasst von Xin Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lymphatic Metastasis, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beijing Chao-Yang Hospital.
Abstract (Originalsprache)
Introduction
Lung adenocarcinoma (LUAD) is a common pathological type of lung cancer. The presence of lymph node metastasis plays a crucial role in determining the overall treatment approach and long‐term prognosis for early LUAD, therefore accurate prediction of lymph node metastasis is essential to guide treatment decisions and ultimately improve patient outcomes.
Methods
We performed transcriptome sequencing on T1 LUAD patients with positive or negative lymph node metastases and combined this data with The Cancer Genome Atlas Program cohort to identify potential risk molecules at the tissue level. Subsequently, by detecting the expression of these risk molecules by real‐time quantitative PCR in serum samples, we developed a model to predict the risk of lymph node metastasis from a training cohort of 96 patients and a validation cohort of 158 patients.
Results
Through transcriptome sequencing analysis of tissue samples, we identified 11 RNA (miR‐412, miR‐219, miR‐371, FOXC1, ID1, MMP13, COL11A1, PODXL2, CXCL13, SPOCK1 and MECOM) associated with positive lymph node metastases in T1 LUAD. As the expression of FOXC1 and COL11A1 was not detected in serum, we constructed a predictive model that accurately identifies patients with positive lymph node metastases using the remaining nine RNA molecules in the serum of T1 LUAD patients. In the training set, the model achieved an area under the curve (AUC) of 0.89, and in the validation set, the AUC was 0.91.
Conclusions
We have established a new risk prediction model using serum samples from T1 LUAD patients, enabling noninvasive identification of those with positive lymph node metastases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
- Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Xin Li, Ming-Ming Shao, Hui Li
Förderung
- Beijing Chao-Yang Hospital
Zitieren
APA
Li, X., Gu, Y., Hu, B., Shao, M. M., & Li, H. (2024). A liquid biopsy assay for the noninvasive detection of lymph node metastases in T1 lung adenocarcinoma. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15315
Vancouver
Li X, Gu Y, Hu B, Shao MM, Li H. A liquid biopsy assay for the noninvasive detection of lymph node metastases in T1 lung adenocarcinoma. Thoracic Cancer. 2024. doi:10.1111/1759-7714.15315
BibTeX
@article{Li2024,
author = {Li, Xin and Gu, Yang and Hu, Bin and Shao, Ming-Ming and Li, Hui},
title = {A liquid biopsy assay for the noninvasive detection of lymph node metastases in T1 lung adenocarcinoma},
journal = {Thoracic Cancer},
year = {2024},
doi = {10.1111/1759-7714.15315}
}
EUVIMED